BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line
Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line Read More »
